Antineoplastic AgentsRadiation InjuriesAntineoplastic Combined Chemotherapy ProtocolsRadiation DosageRadiation, IonizingNeoplasmsCell Line, TumorDose-Response Relationship, RadiationDrug Screening Assays, AntitumorDoxorubicinCombined Modality TherapyRadiation ToleranceRadiotherapyCisplatinRadiotherapy DosageChemotherapy, AdjuvantRadiationDrug Resistance, NeoplasmApoptosisAntineoplastic Agents, PhytogenicRadiation OncologyRadiation ProtectionRadiotherapy, ConformalRadiotherapy, Intensity-ModulatedAntibiotics, AntineoplasticRadiation MonitoringTreatment OutcomeCell SurvivalEtoposideBreast NeoplasmsRadiotherapy, AdjuvantDose FractionationPaclitaxelDrug Delivery SystemsTumor Cells, CulturedXenograft Model Antitumor AssaysRadiation PneumonitisRadiation-Sensitizing AgentsRadiotherapy Planning, Computer-AssistedMice, NudeDrug CarriersLung NeoplasmsCamptothecinBrachytherapyBrain NeoplasmsCell ProliferationNeoplasm StagingDNA DamageNeoplasm Recurrence, LocalDose-Response Relationship, DrugEllipticinesCyclophosphamideGamma RaysDisease-Free SurvivalTime FactorsRadiometrySurvival AnalysisNeoplasms, Radiation-InducedDrug Resistance, MultipleP-GlycoproteinAntimetabolites, AntineoplasticRadiation Injuries, ExperimentalAdenocarcinomaVinblastineRadiosurgeryInhibitory Concentration 50Head and Neck NeoplasmsAntineoplastic Agents, AlkylatingBleomycinSurvival RateOrganoplatinum CompoundsPrognosisCranial IrradiationDrug SynergismMolecular StructureFluorouracilCosmic RadiationCarcinoma, Squamous CellCell CycleDrug DesignDaunorubicinMitomycinProstatic NeoplasmsCarboplatinRadiotherapy, Computer-AssistedMethotrexateNeoadjuvant TherapyTumor BurdenDrug Administration ScheduleProdrugsClinical Trials as TopicGene Expression Regulation, NeoplasticDNA Topoisomerases, Type IIPlatinumDacarbazineColonic NeoplasmsCarcinoma, Non-Small-Cell LungParticle AcceleratorsRadiation-Protective AgentsDeoxycytidine